AU2002256005A1 - Control of glycoforms in igg - Google Patents

Control of glycoforms in igg

Info

Publication number
AU2002256005A1
AU2002256005A1 AU2002256005A AU2002256005A AU2002256005A1 AU 2002256005 A1 AU2002256005 A1 AU 2002256005A1 AU 2002256005 A AU2002256005 A AU 2002256005A AU 2002256005 A AU2002256005 A AU 2002256005A AU 2002256005 A1 AU2002256005 A1 AU 2002256005A1
Authority
AU
Australia
Prior art keywords
glycoforms
igg
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002256005A
Inventor
Ruth L. Devries
Thomas B. Vickroy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002256005A1 publication Critical patent/AU2002256005A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
AU2002256005A 2001-03-27 2002-03-27 Control of glycoforms in igg Abandoned AU2002256005A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27902601P 2001-03-27 2001-03-27
US60/279,026 2001-03-27
PCT/US2002/009998 WO2002076578A1 (en) 2001-03-27 2002-03-27 Control of glycoforms in igg

Publications (1)

Publication Number Publication Date
AU2002256005A1 true AU2002256005A1 (en) 2002-10-08

Family

ID=23067363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002256005A Abandoned AU2002256005A1 (en) 2001-03-27 2002-03-27 Control of glycoforms in igg

Country Status (4)

Country Link
EP (1) EP1373547A4 (en)
JP (1) JP2005509403A (en)
AU (1) AU2002256005A1 (en)
WO (1) WO2002076578A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101681396A (en) * 2007-04-16 2010-03-24 动量制药公司 Glucoprotein product that limits and associated method
KR101637533B1 (en) * 2007-08-20 2016-07-11 글락소 그룹 리미티드 Production method
KR20160084500A (en) 2009-10-26 2016-07-13 에프. 호프만-라 로슈 아게 Method for the production of a glycosylated immunoglobulin
CN102869784A (en) 2010-04-07 2013-01-09 动量制药公司 High mannose glycans
EP3862423A1 (en) 2010-04-26 2021-08-11 Novartis AG Improved cell cultivation process
WO2012125553A2 (en) 2011-03-12 2012-09-20 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing n-glycans in glycoprotein products
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc Methods related to ctla4-fc fusion proteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2015000865A1 (en) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
EA201690171A1 (en) * 2013-07-06 2016-06-30 Кадила Хелзкэр Лимитед IMPROVED METHOD OF OBTAINING MONOCLONAL ANTIBODIES
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
TR201610497T1 (en) * 2014-01-29 2017-06-21 Lg Chemical Ltd METHOD OF MODULING RECOMBINANT PROTEIN GALACTOSILATION BY THE OPTIMIZATION OF THE CULTURAL ENVIRONMENT

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1304918A (en) * 1919-05-27 Exlter medium ob other abticiie of mauufactitbe
US1898027A (en) * 1929-01-10 1933-02-21 Charles A Winslow Air filter
US2271662A (en) * 1939-01-17 1942-02-03 Rubissow George Alexis Filtering element and new method for its manufacture
US2217370A (en) * 1939-08-08 1940-10-08 Socony Vacuum Oil Co Inc Screen wrapped perforated liner pipe
US3383278A (en) * 1967-09-27 1968-05-14 Appleton Mills Adjustable woven fabric
US3502116A (en) * 1967-11-29 1970-03-24 Nat Standard Co Woven filter cloth
US4048075A (en) * 1974-05-06 1977-09-13 The Carborundum Company Filter cartridge
US5256291A (en) * 1992-04-16 1993-10-26 Cagle William S Screen for filtering undesirable particles from a liquid
US5673483A (en) * 1994-05-25 1997-10-07 Morton International, Inc. Method for constructing an inflator filter made of wrapped mesh
US5711879A (en) * 1996-03-04 1998-01-27 American Metal Fibers Radial-flow filter and method of manufacture
DE59813187D1 (en) * 1997-12-03 2005-12-15 Roche Diagnostics Gmbh PROCESS FOR THE PREPARATION OF POLYPEPTIDES WITH APPROPRIATE GLYCOSILATION
EP1150762B1 (en) * 1999-02-02 2002-12-11 N.V. Bekaert S.A. Tow wound filter cartridge
AU778046B2 (en) * 1999-04-26 2004-11-11 Genentech Inc. Cell culture process for glycoproteins

Also Published As

Publication number Publication date
EP1373547A4 (en) 2006-01-18
WO2002076578A1 (en) 2002-10-03
WO2002076578A9 (en) 2003-03-06
JP2005509403A (en) 2005-04-14
EP1373547A1 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
AU2002256005A1 (en) Control of glycoforms in igg
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002303846A1 (en) Co-axial control valve
AU2002366770A1 (en) Member having photocatalytic function and method for manufacture thereof
AU2001288024A1 (en) Dose control in ct-images
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2002333819A1 (en) Methods for controlling screenouts
AU2002365649A1 (en) Anti-dota antibody
AU2002335057A1 (en) Controller selectable hyperlinks
AUPR546801A0 (en) Recombinant antibodies
AU2002357934A1 (en) Humanized lactoferrin and uses thereof
AU2002368012A1 (en) Hematology reference control
AU2002303560A1 (en) Integrated control center environment
GB0104299D0 (en) Immunoglobulin control region
AU2002226967A1 (en) Chair control
AU2002307605A1 (en) User interface and means for controlling same
AU2002365524A1 (en) Charging control method and charging controller
AU2002355988A1 (en) Control valves
AU2002211364A1 (en) Human anti-cd40 antibodies
AU2002236139A1 (en) Control valve
AUPR433201A0 (en) Control valve
AU2002338151A1 (en) Control valve
AU2002330563A1 (en) Control valve
AU2002352461A1 (en) Control system and method
AU2002257630A1 (en) Human mrp5-like protein

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase